Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03780907
Other study ID # E2007-E049-203
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date February 14, 2003
Est. completion date August 6, 2003

Study information

Verified date November 2015
Source Eisai Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objectives of this study were to assess the tolerability and safety of E2007 in patients with refractory partial or generalised seizures and to assess the pharmacokinetics of E2007 in epileptic patients receiving at least one concomitant anti-epileptic drug.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date August 6, 2003
Est. primary completion date August 6, 2003
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria

A patient who met the following inclusion criteria was eligible to participate in the study:

1. Males or females with simple or complex partial seizures with or without secondary generalization, or primary generalized tonic-clonic seizures according to the International League against Epilepsy classification. Patient records were to document the frequency of seizure.

2. Age: 18 to 65 years.

3. Race: any.

4. Patients receiving up to two additional anti-epileptic medications at doses that were stable for at least the four weeks immediately preceding baseline.

5. Patients willing and able to co-operate with the study procedures including completion of patient diaries.

6. Patients living at home with a partner or carer able to monitor compliance.

7. Patients giving informed consent to participate in the study.

Exclusion Criteria

A patient who met the following exclusion criteria was not eligible to participate in the study:

1. Pregnant or lactating women.

2. Women of childbearing potential unless (1) surgically sterile or (2) practicing effective contraception (eg, abstinence, IUD or barrier method plus hormonal method) and having a negative serum beta-HCG result at screening and being willing to remain on the current form of contraception for the duration of the study. Postmenopausal women could be included but were to have been amenorrhoeic for at least 12 months to be considered as not being of child-bearing potential.

3. Fertile men not willing to use reliable contraception or with partners not willing to use reliable contraception.

4. Patients with status epilepticus within the past 24 months.

5. Patients with unstable abnormalities of the hepatic, renal, cardiovascular, respiratory, abdominal, haematological, endocrine or metabolic systems which might complicate assessment of the tolerability of the study medication.

6. Patients with significantly elevated liver enzymes (abnormal bilirubin level, or serum transaminase levels more than 1.5 times the upper limit of normal).

7. Patients taking drugs other than anti-epileptic agents which induce the enzyme cytochrome P450 3A4 (since these might reduce the plasma concentration of E2007), including dexamethasone, rifabutin, rifampacin, St John's Wort.

8. Patients with past or present drug or alcohol abuse.

9. Patients with unstable psychiatric illness.

10. Patients who had received an investigational drug within the three months before baseline.

11. Patients without a reliable partner or carer.

12. Patients with any condition which would make the patient, in the opinion of the investigator, unsuitable for the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
E2007
1 mg of E2007 was administered by mouth once daily.
E2007
2 mg of E2007 was administered by mouth once daily.
Placebo
Placebo once daily of oral tablet formulation to be taken in the morning, one hour before breakfast, with a glass of water.

Locations

Country Name City State
Germany 3ClinicalResearch AG Hennigsdorf

Sponsors (1)

Lead Sponsor Collaborator
Eisai Co., Ltd.

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with Treatment Emergent Adverse Events (TEAEs) The TEAEs were defined as those Adverse Events (AEs) that start on or after the first dose of the treatment until the end of the study. AEs were classified by the investigator as 'not related', 'possibly related' or 'probably related'. From administration of first dose of study drug up until 42 days.
Primary Clinical Global Impression of Tolerability (CGIT) The investigator's global impressions of the tolerability of the study treatment was based on a five point scale: 1 - very good, 2 - good, 3 - moderate, 4 - poor, and 5 - very poor. Day 28
Primary Pharmacokinetic Parameter: Area Under the Curve (AUC)(0-24hr) of E2007 Standard pharmacokinetic parameters for E2007 were derived from plasma drug concentrations in epileptic participants. A measure of systemic drug exposure over 24 hours, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. Day 1 and Day 14
Primary Pharmacokinetic Parameter: Cmax (Maximum Observed Plasma Concentration) of E2007 Standard pharmacokinetic parameters for E2007 were derived from plasma drug concentrations in epileptic participants. The maximum concentration of a drug observed after its administration. Day 1 and Day 14
Primary Pharmacokinetic Parameter: Tmax (Time to Maximum Concentration) of E2007 Standard pharmacokinetic parameters for E2007 were derived from plasma drug concentrations in epileptic participants. The time after dosing when a drug attains its highest measurable concentration (Cmax). Day 1 and Day 14
Primary Pharmacokinetic Parameter: Css,min (Minimum Steady State Plasma Concentration) of E2007 Standard pharmacokinetic parameters for E2007 were derived from plasma drug concentrations in epileptic participants. Lowest plasma concentration within a steady-state dosing interval. Day 14
Primary Pharmacokinetic Parameter: Cav (Average Plasma Concentration) of E2007 Standard pharmacokinetic parameters for E2007 were derived from plasma drug concentrations in epileptic participants. Day 14
Primary Pharmacokinetic Parameter: Peak-to-trough Fluctuation (PTF) of E2007 Standard pharmacokinetic parameters for E2007 were derived from plasma drug concentrations in epileptic participants. Day 14
Primary Pharmacokinetic Parameter: Observed Accumulation Ratio (Rac) of E2007 Standard pharmacokinetic parameters for E2007 were derived from plasma drug concentrations in epileptic participants. Day 14
Secondary Change from Baseline of Bond and Lader Scale The Bond and Lader visual analogue mood scale (VAMS) had a score from 0 - 100; a higher score represented worsening of the participants condition attributed to 3 factors, (1) Anxiety (e.g., calmness), (2) Sedation (e.g., alertness, (3) Dysphoria (e.g., contentedness). The change was visit minus baseline. Baseline, Day 28 and Day 42
Secondary Change from Baseline of Peak Saccadic Velocity (PSV) Saccadic velocity is the rate of eye movement in response to stimulus. The saccadic eye movement was used to allow comparison of any sedative effects seen. Baseline, Day 28, Day 42
Secondary Number of Particpants receiving other Anti-epileptic agents During Treatment Day 1 and Day 14
Secondary Percent Change from Baseline of Failed Saccades Failed saccades is stimulus resulting in no eye movement above a defined threshold within a specified time. Baseline, Day 28, Day 42
Secondary Mean trough concentrations of E2007 Day 7, Day 21, and Day 28
Secondary Number of seizures Baseline (Day-1) to Day 42
Secondary The Clinical Global Impression of Change Day 28
See also
  Status Clinical Trial Phase
Completed NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02909387 - Adapting Project UPLIFT for Blacks in Georgia N/A
Completed NCT05552924 - Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients N/A
Terminated NCT01668654 - Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS Phase 3
Not yet recruiting NCT05068323 - Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients N/A
Completed NCT03994718 - Creative Arts II Study N/A
Recruiting NCT04076449 - Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Completed NCT00782249 - Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Active, not recruiting NCT06034353 - Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients N/A
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Not yet recruiting NCT05559060 - Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
Completed NCT02646631 - Behavioral and Educational Tools to Improve Epilepsy Care N/A
Completed NCT02952456 - Phenomenological Approach of Epilepsy in Patients With Epilepsy
Completed NCT02977208 - Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use Phase 4
Recruiting NCT02539134 - TAK-935 Multiple Rising Dose Study in Healthy Participants Phase 1
Completed NCT02491073 - Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL) N/A
Terminated NCT02757547 - Transcranial Magnetic Stimulation for Epilepsy N/A